Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in ...

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its quarterly report, with the stock down 15% to US$6.29. Revenue was dismal, with revenues of US$22m ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Q2 2025 Management View John G. Houston, Chairperson, CEO & President, stated the quarter was eventful with "significant clinical and regulatory programs across our pipeline of PROTAC degraders." He ...

For example, Arvinas, Inc. (NASDAQ:ARVN) shareholders have seen the share price rise 80% over three years, well in excess of the market return (41%, not including dividends).

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

Arvinas Inc. Annual stock financials by MarketWatch. View the latest ARVN financial statements, income statements and financial ratios.

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Contacts Investors: Jeff Boyle +1 (347) 247-5089 ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

Arvinas has also granted the underwriters a 30-day option to buy an additional 857,142 shares at the public offering price. The $400 million offering is expected to close on Friday, subject to ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, reached an all-time high of $108 in July of this year ...

Shares of Arvinas (ARVN -2.02%) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (PFE -0.04%).